Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 1671 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Montero-Odasso M, Sarquis-Adamson Y, Song HY, Bray NW, Pieruccini-Faria F, Speechley M. Polypharmacy, gait performance, and falls in community-dwelling older adults. Results from the Gait and Brain Study. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103158]
2. Cita con resumen
Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]
3. Cita con resumen
Randolph AC, Lin Y-L, Volpi E, Kuo Y-F. Tricyclic antidepressant and/or ?-aminobutyric acid–analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103149]
4.Enlace a cita original Cita con resumen
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019;176:1 de junio. [Ref.ID 103133]
5. Cita con resumen
Anónimo. Ginkgo biloba: to be avoided due to severe adverse effects. Prescrire Int 2019;28:155-6. [Ref.ID 103129]
6.Enlace a cita original Cita con resumen
Thiels CA, Habermann EB, Heffery MM. Chronic use of tramadol after acute pain episode: cohort study. BMJ 2019;365:14 de mayo. [Ref.ID 103126]
7.Enlace a cita original Cita con resumen
Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]
8.Enlace a cita original Cita con resumen
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]
9.Enlace a cita original Cita con resumen
10.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
11.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]
12.Enlace a cita original Cita con resumen
Monte AA, Shelton SK, Mills E, Saben J, Hopkinson A, Sonn B, Devivo M, Chang T, Fox J, Brevik C, Williamson K, Abbott D. Acute illness associated with cannabis use, by route of exposure: an observational study. Ann Intern Med 2019:26 de marzo. [Ref.ID 103069]
13.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]
16.Enlace a cita original Cita con resumen
Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019;364:6 de marzo. [Ref.ID 103059]
18.Enlace a cita original Cita con resumen
Gobbi G, Atkin T, Zytnski T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. JAMA Psychiatry 2019;76:13 de febrero. [Ref.ID 103030]
19.Enlace a cita original Cita con resumen
Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]
20.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
Seleccionar todas
 
 1 a 20 de 1671 siguiente >>